MSC and Exosome Therapies Show Promise Against Four Major Age-Related Diseases
A comprehensive review maps how mesenchymal stem cells and their exosomes combat Alzheimer's, atherosclerosis, osteoporosis, and ovarian failure.
Summary
Mesenchymal stem cells (MSCs) and the tiny vesicles they release called exosomes are emerging as powerful tools against age-related diseases. This 2025 review from the Chinese Academy of Medical Sciences synthesizes preclinical and clinical evidence showing that MSCs from sources like bone marrow, umbilical cord, and adipose tissue can repair aging tissues through three core mechanisms: differentiating into replacement cells, secreting healing growth factors, and calming harmful inflammation. Their exosomes — nano-sized cargo carriers loaded with proteins and microRNAs — can deliver these benefits without the risks of live cell transplantation. The review covers applications in premature ovarian failure, Alzheimer's disease, atherosclerosis, and osteoporosis, while acknowledging that poor cell survival, immune rejection, and uneven distribution remain hurdles before these therapies reach widespread clinical use.
Detailed Summary
Population aging is a major global challenge, with the number of people aged 60 and over projected to double worldwide by 2050. Against this backdrop, mesenchymal stem cells (MSCs) and their secreted exosomes (MSC-Exos) have emerged as one of the most versatile biological platforms for tackling the cellular dysfunctions that drive age-related disease. This comprehensive review from Li and Bai at the Institute of Laboratory Animal Science, CAMS & PUMC (published July 2025 in Stem Cell Research & Therapy), synthesizes preclinical and early clinical evidence across four priority age-related conditions: premature ovarian failure (POF), Alzheimer's disease (AD), atherosclerosis (AS), and osteoporosis (OP).
MSCs originate from the mesodermal layer and have been isolated from bone marrow, umbilical cord, adipose tissue, umbilical cord blood, dental pulp, placenta, amniotic membrane, synovial membrane, and perivascular tissues. Their therapeutic activity rests on three pillars described in the review: differentiation into various cell types, secretion of bioactive paracrine factors, and immunomodulatory regulation of inflammation. MSC-Exos — nano-sized vesicles loaded with proteins, microRNAs, and other biomolecules — can deliver MSC-derived signaling cargo to target cells with comparable therapeutic benefit to live MSCs, while avoiding some of the risks of cell transplantation.
For premature ovarian failure, the review highlights rodent studies in which umbilical cord-derived MSCs (hUC-MSCs) restored ovarian function in cyclophosphamide-induced POF models via the PI3K/AKT/mTOR pathway by reducing granulosa cell over-autophagy through paracrine VEGFA secretion. Adipose-derived MSCs (AD-MSCs) were reported to outperform UC-MSCs in improving ovarian function in naturally aged mice. Preconditioning and delivery strategies — including hyaluronic acid scaffolds, 3D bioprinted engineered ovaries, collagen scaffolds, and mitochondrial transfer — enhanced MSC retention and revascularization. The review also describes miR-21 as an active exosomal cargo, with miR-21-enriched UC-MSCs improving ovarian recovery in a ZP3-induced POF mouse model by inhibiting the PTEN/AKT/FOXO3a pathway and upregulating CD8+CD28- regulatory T cells.
In Alzheimer's disease models, hUC-MSCs cocultured with neural stem cells from 5XFAD transgenic mice induced neurogenesis via activin A signaling, and in SAMP8 accelerated-aging mice, MSC treatment reduced amyloid-beta burden and improved cognition. MSC-Exos carrying specific microRNAs were reported to cross the blood-brain barrier and deliver neuroprotective cargo to hippocampal neurons — a notable advantage over whole-cell therapies. For atherosclerosis and osteoporosis, MSC-Exos carrying anti-inflammatory miRNAs and osteogenic factors showed plaque stabilization and bone density preservation in preclinical models.
The review also benchmarks tissue-source selection: bone marrow MSCs tend to favor osteogenic and hematopoietic applications, adipose-derived MSCs show strong angiogenic and ovarian outcomes, and UC-MSCs offer high yield and low immunogenicity for neurological and reproductive conditions. Despite compelling preclinical data, the authors catalog major barriers to clinical translation: uneven biodistribution after systemic delivery, poor survival in aged in vivo environments, apoptosis of transplanted cells, potential immune responses, and the technical complexity of scaling GMP-grade exosome manufacturing. No large randomized controlled trials yet demonstrate definitive efficacy in humans for these indications. The authors call for multidisciplinary collaboration to develop optimized preconditioning, delivery, and manufacturing strategies.
Key Findings
- Adipose-derived MSCs outperformed umbilical cord-derived MSCs in restoring ovarian function in naturally aged mice (ovarian injection, 3.5×10⁵ cells, 3-week follow-up)
- hUC-MSCs reduced granulosa cell over-autophagy via paracrine VEGFA and regulated PI3K/AKT/mTOR signaling in cyclophosphamide-induced POF rats (1×10⁶ cells IV, 28-day follow-up)
- miR-21-enriched UC-MSCs improved ovarian recovery in ZP3-induced POF mice by inhibiting the PTEN/AKT/FOXO3a pathway and upregulating CD8+CD28- T regulatory cells (1×10⁶ cells IV, 1-week follow-up)
- Amniotic membrane-derived MSCs improved premature aging phenotype in Bmi-1-deficient mice after intraperitoneal injection of 1×10⁷ cells with measurable effects at 21 days
- Hyaluronic acid scaffolds combined with UC-MSCs enhanced ovarian senescence treatment in both VCD-induced POF and naturally aged mouse models (1×10⁵ cells, 14-day follow-up)
- MSC-Exos from the ExoCarta database now contain catalogued data on over 9,000 proteins and 3,400 RNAs, supporting their use as an alternative to whole-cell therapy with reduced pulmonary embolism risk
- 3D bioprinted engineered ovaries composed of integrated vascular architecture and hAD-MSCs significantly improved MSC retention and revascularization in grafts in CTX-induced POF rats (1×10⁷ cells, 4-week follow-up)
Methodology
This is a comprehensive narrative review article, not a primary clinical trial. The authors systematically synthesized preclinical rodent studies (using chemotherapy-induced, radiation-induced, and naturally aged animal models) and select early-phase clinical data across four disease categories. Study designs in cited preclinical work ranged from 1-week to 1-year follow-up periods, used cell doses between 1×10⁵ and 1×10⁷, and employed intravenous, intraovarian, intraperitoneal, and intramuscular delivery routes. No pooled meta-analysis or formal statistical synthesis was performed across studies.
Study Limitations
This is a narrative review without formal systematic review or meta-analytic methodology, meaning selection bias in cited studies cannot be excluded. The overwhelming majority of cited evidence is from rodent preclinical models, with very limited human clinical trial data, which significantly constrains the strength of clinical conclusions. The authors acknowledge persistent translational barriers including poor in vivo MSC survival, heterogeneous biodistribution, potential immune reactions, and the absence of standardized GMP-grade exosome manufacturing protocols.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.